<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153344</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190937</org_study_id>
    <secondary_id>2019-A02526-51</secondary_id>
    <nct_id>NCT04153344</nct_id>
  </id_info>
  <brief_title>Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis</brief_title>
  <acronym>NEF-1</acronym>
  <official_title>Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to study the function of the pigment epithelium in patients
      with neurofibromatosis type 1 using electro-oculogram to confirm abnormally high values
      reported in previous studies, but also to correlate this hyperactivity of the pigment
      epithelium with the presence and size of choroidal hyperreflective areas observed in
      infra-red imaging of the fundus.

      The hypothesis of the study is that the function of the pigment epithelium measured by the
      electro-oculogram correlates with the surface of choroidal hyperreflective areas. Finally,
      the potential consequences of a supra-normal function of the pigment epithelium on the global
      retinal function are not known. A full-field electroretinogram will evaluate the global
      neurosensory retinal function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with neurofibromatosis type 1 have numerous eye problems: glioma of the optic
      pathways, Lisch nodules, palpebral involvement by plexiform neurofibromas, orbital dysplasia,
      etc. With the emergence of multimodal imaging in ophthalmology a new ocular involvement has
      been described: choroidal hyperreflective areas. They are located in the most superficial
      layers of the choroid, adjacent to the retinal pigment epithelium, visible only on infra-red
      imaging of the fundus. These areas are frequently observed, about 90% in adults and 70 to 80%
      in children. With a sensitivity of 0.83 and a specificity of 0.96, these lesions would have
      their place as a diagnostic criterion for neurofibromatosis type 1.

      In parallel, two successive studies have evaluated the function of the retinal pigment
      epithelium using electro-oculograms; they showed in patients with neurofibromatosis type 1 a
      significant increase in the Arden ratio, reflecting hyperactivity of the pigment epithelium.

      The objective of this study is to study the function of the pigment epithelium in patients
      with neurofibromatosis type 1, using electro-oculogram to confirm these abnormally high
      values, but also to correlate this hyperactivity of the pigment epithelium to the presence
      and total area of choroidal lesions observed in infra-red imaging of the fundus.

      The hypothesis of the study is that the function of the pigment epithelium measured by the
      electro-oculogram correlates with the surface of the choroidal hyperreflective areas.
      Finally, the potential consequences of a supra-normal function of the pigment epithelium on
      the global retinal function are not known. A full-field electroretinogram will evaluate the
      global neurosensory retinal function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">May 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dark trough value</measure>
    <time_frame>12 months</time_frame>
    <description>Electro-oculogram : dark trough value (μV).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Light/dark (Arden) ratio</measure>
    <time_frame>12 months</time_frame>
    <description>Electro-oculogram : ratio between the light and dark potentials.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and area of infrared hyperreflective areas</measure>
    <time_frame>12 months</time_frame>
    <description>Infrared fundus picture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Values of the amplitudes</measure>
    <time_frame>12 months</time_frame>
    <description>Electroretinogram : values of the amplitudes (μV) of a- and/or b-waves for dark-adapted 0.01, dark adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, and light-adapted 3.0 flicker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Values of the peak times</measure>
    <time_frame>12 months</time_frame>
    <description>Electroretinogram : values of the peak times (ms) of a- and/or b-waves for dark-adapted 0.01, dark adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, and value of the peak-to-peak time (ms) for light-adapted 3.0 flicker.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neurofibromatosis Type 1</condition>
  <arm_group>
    <arm_group_label>Infrared hyperreflective area</arm_group_label>
    <description>Patients with neurofibromatosis type 1 and with infrared hyperreflective areas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No infrared hyperreflective areas</arm_group_label>
    <description>Patients with neurofibromatosis type 1 and with no infrared hyperreflective areas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Patients with no neurofibromatosis type 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electro-oculogram</intervention_name>
    <description>Electrophysiological recording of changes in electrical potential across the retinal pigmentary epithelium during successive periods of dark and light adaptation, according to ISCEV standards. Results will comprise dark trough value and light/dark (Arden) ratio.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Infrared hyperreflective area</arm_group_label>
    <arm_group_label>No infrared hyperreflective areas</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Full-field electroretinogram</intervention_name>
    <description>Electrophysiological recording of retinal function. Results will comprise amplitudes and latencies of each electroretinography response (dark-adapted 0.01, dark-adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, light-adapted 3.0 flicker).</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Infrared hyperreflective area</arm_group_label>
    <arm_group_label>No infrared hyperreflective areas</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients consulting the ophthalmology department of Necker-Enfants Malades Hospital:

          -  10 patients with neurofibromatosis type 1 without infrared hyperreflective areas

          -  10 patients with neurofibromatosis type 1 and infrared hyperreflective areas

          -  10 control patients with no retinal disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with neurofibromatosis type 1, aged 7 years or older:

               -  Presence of hyper-reflective choroidal lesions in infra-red imaging in the group
                  with choroidal lesions.

               -  Absence of hyper-reflective choroidal lesions in infra-red imaging in the group
                  without choroidal lesions.

          -  Control patients free from retinal or choroidal pathology, matched for age to patients
             in the group with neurofibromatosis type 1.

          -  Patients consulting the ophthalmology department of Necker-Enfants Malades Hospital.

          -  Non-opposition of the holders of the parental authority and the minor patient;
             non-opposition of the major patient.

        Exclusion Criteria:

          -  Impossibility to perform an electro-oculogram, especially because of an oculomotor
             disorder, or an electroretinogram, for example because of hyperactivity.

          -  Significant impairment of visual function.

          -  Retinal pathology proved.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthieu Robert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique Brémond-Gignac, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthieu Robert, MD, PhD</last_name>
    <phone>+33 1 44 49 53 62</phone>
    <email>matthieu.robert@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène Morel</last_name>
    <phone>+33 1 71 19 63 46</phone>
    <email>helene.morel@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu Robert, MD, PhD</last_name>
      <phone>+33 1 44 49 53 62</phone>
      <email>matthieu.robert@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Hélène Morel</last_name>
      <phone>+33 1 71 19 63 46</phone>
      <email>helene.morel@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Abitbol, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Lubiński W, Zajaczek S, Sych Z, Penkala K, Palacz O, Lubiński J. Electro-oculogram in patients with neurofibromatosis type 1. Doc Ophthalmol. 2001 Sep;103(2):91-103.</citation>
    <PMID>11720259</PMID>
  </reference>
  <reference>
    <citation>Viola F, Villani E, Natacci F, Selicorni A, Melloni G, Vezzola D, Barteselli G, Mapelli C, Pirondini C, Ratiglia R. Choroidal abnormalities detected by near-infrared reflectance imaging as a new diagnostic criterion for neurofibromatosis 1. Ophthalmology. 2012 Feb;119(2):369-75. doi: 10.1016/j.ophtha.2011.07.046. Epub 2011 Oct 2.</citation>
    <PMID>21963267</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurofibromatosis type 1</keyword>
  <keyword>Infrared hyperreflective areas</keyword>
  <keyword>Hyperactivity of the pigment epithelium</keyword>
  <keyword>Electro-oculogram</keyword>
  <keyword>Electroretinogram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

